Business PR Newswire Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM rvrisingnetwork October 21, 2025 0 In the OptiTROP-Lung04 trial, a total of 376 patients were randomized (1:1) to receive sac-TMT monotherapy or... Read More Read more about Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
Business PR Newswire Kelun-Biotech’s Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC rvrisingnetwork October 18, 2025 0 CHENGDU, China, Oct. 17, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that the Company’s human epidermal growth factor... Read More Read more about Kelun-Biotech’s Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC